Cerebral Glucose Metabolism Is a Valuable Predictor of Survival in Patients with Lewy Body Diseases.
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
18 Jun 2024
18 Jun 2024
Historique:
revised:
22
04
2024
received:
28
12
2023
accepted:
17
05
2024
medline:
18
6
2024
pubmed:
18
6
2024
entrez:
18
6
2024
Statut:
aheadofprint
Résumé
Patients with Lewy body diseases have an increased risk of dementia, which is a significant predictor for survival. Posterior cortical hypometabolism on [ We enrolled patients diagnosed with Parkinson's disease (PD), Parkinson's disease with dementia, or dementia with Lewy bodies who underwent [ Glucose metabolism was a significant predictor of survival in 259 included patients (n = 118 events; hazard ratio: 1.4 [1.2-1.6] per Z-score; hazard ratio: 1.8 [1.5-2.2] per visual PET rating score; both p < 0.0001). Risk stratification with visual PET rating scores yielded a median survival of 4.8, 6.8, and 12.9 years for patients with severe, moderate, and mild posterior cortical hypometabolism (median survival not reached for normal cortical metabolism). Stratification into 5 groups based on the prognostic index revealed 10-year survival rates of 94.1%, 78.3%, 34.7%, 0.0%, and 0.0%. Regional cerebral glucose metabolism is a significant predictor of survival in Lewy body diseases and may allow an earlier survival prediction than the clinical milestone "dementia." Thus, [
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Berta-Ottenstein Program for Advanced Clinician Scientist, Faculty of Medicine, University of Freiburg
Organisme : Walter Benjamin Fellowship from the German Research Foundation (Deutsche Forschungsgemeinschaft; DFG)
Organisme : Hans A. Krebs Medical Scientist Program, Faculty of Medicine, University of Freiburg
Informations de copyright
© 2024 The Author(s). Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology 2017;89:88–100.
Gonzalez MC, Dalen I, Maple‐Grødem J, et al. Parkinson's disease clinical milestones and mortality. NPJ Parkinsons Dis 2022;8:58.
Lawson RA, Yarnall AJ, Duncan GW, et al. Cognitive decline and quality of life in incident Parkinson's disease: the role of attention. Parkinsonism Relat Disord 2016;27:47–53.
Buter TC, Van Den Hout A, Matthews FE, et al. Dementia and survival in Parkinson disease: a 12‐year population study. Neurology 2008;70:1017–1022.
Van De Beek M, Ooms FAH, Ebenau JL, et al. Association of the ATN research framework with clinical profile, cognitive decline, and mortality in patients with dementia with Lewy bodies. Neurology 2022;98:e1262–e1272.
Savica R, Grossardt BR, Bower JH, et al. Survival and causes of death among people with clinically diagnosed synucleinopathies with parkinsonism. JAMA Neurol 2017;74:839–846.
Bäckström D, Granåsen G, Domellöf ME, et al. Early predictors of mortality in parkinsonism and Parkinson disease. Neurology 2018;91:e2045–e2056.
Cools R. Dopaminergic modulation of cognitive function‐implications for L‐DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 2006;30:1–23.
Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013;80:800–809.
Dorsey ER, Elbaz A, Nichols E, et al. Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 2018;17:939–953.
Deuschl G, Antonini A, Costa J, et al. European Academy of Neurology/Movement Disorder Society‐European section guideline on the treatment of Parkinson's disease: I invasive therapies. Mov Disord 2022;37:1360–1374.
Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197–211.
McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113–1124.
Parkkinen L, Pirttilä T, Alafuzoff I. Applicability of current staging/categorization of α‐synuclein pathology and their clinical relevance. Acta Neuropathol 2008;115:399–407.
Weintraub D. What's in a name? The time has come to unify Parkinson's disease and dementia with Lewy bodies. Mov Disord 2023;38:1977–1981.
Meyer PT, Frings L, Rucker G, Hellwig S. (18)F‐FDG PET in parkinsonism: differential diagnosis and evaluation of cognitive impairment. J Nucl Med 2017;58:1888–1898.
Firbank MJ, Yarnall AJ, Lawson RA, et al. Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE‐PD study. J Neurol Neurosurg Psychiatry 2017;88:310–316.
Bohnen NI, Koeppe RA, Minoshima S, et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 2011;52:848–855.
Pilotto A, Premi E, Paola Caminiti S, et al. Single‐subject SPM FDG‐PET patterns predict risk of dementia progression in Parkinson disease. Neurology 2018;90:e1029–e1037.
Booth S, Park KW, Lee CS, Ko JH. Predicting cognitive decline in Parkinson's disease using FDG‐PET‐based supervised learning. J Clin Invest 2022;132:e157074.
Huang C, Mattis P, Tang C, et al. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 2007;34:714–723.
Perovnik M, Rus T, Schindlbeck KA, Eidelberg D. Functional brain networks in the evaluation of patients with neurodegenerative disorders. Nat Rev Neurol 2023;19:73–90.
Mattis PJ, Niethammer M, Sako W, et al. Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases. Neurology 2016;87:1925–1933.
Blazhenets G, Ma Y, Sörensen A, et al. Principal components analysis of brain metabolism predicts development of Alzheimer dementia. J Nucl Med 2019;60:837–843.
Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689–1707.
Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society task force guidelines. Mov Disord 2012;27:349–356.
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30:1591–1601.
Jost ST, Kaldenbach MA, Antonini A, et al. Levodopa dose equivalency in Parkinson's disease: updated systematic review and proposals. Mov Disord 2023;38:1236–1252.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
Semmler C, Stopic V, Jost ST, et al. Preoperative motor deficits and depressive symptoms predict quality of life in patients with Parkinson's disease at different time points after surgery for subthalamic stimulation: a retrospective study. Neurol Res Pract 2024;6:8.
Frings L, Henninger F, Treppner M, et al. [123I]FP‐CIT SPECT in clinically uncertain parkinsonism predicts survival: a data‐driven analysis. J Parkinsons Dis 2020;10:1457–1465.
Bergeron D, Flynn K, Verret L, et al. Multicenter validation of an MMSE‐MoCA conversion table. J Am Geriatr Soc 2017;65:1067–1072.
Spetsieris P, Ma Y, Peng S, et al. Identification of disease‐related spatial covariance patterns using neuroimaging data. J Vis Exp 2013;26:50319.
Brumberg J, Schroter N, Blazhenets G, et al. Differential diagnosis of parkinsonism: a head‐to‐head comparison of FDG PET and MIBG scintigraphy. NPJ Parkinsons Dis 2020;6:39.
Minoshima S, Frey KA, Koeppe RA, et al. A diagnostic approach in Alzheimer's disease using three‐dimensional stereotactic surface projections of fluorine‐18‐FDG PET. J Nucl Med 1995;36:1238–1248.
Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol 2013;13:33.
Fujishiro H, Iseki E, Kasanuki K, et al. A follow up study of non‐demented patients with primary visual cortical hypometabolism: prodromal dementia with Lewy bodies. J Neurol Sci 2013;334:48–54.
de Lau LM, Verbaan D, Marinus J, van Hilten JJ. Survival in Parkinson's disease. Relation with motor and non‐motor features. Parkinsonism Relat Disord 2014;20:613–616.
Keener AM, Paul KC, Folle A, et al. Cognitive impairment and mortality in a population‐based Parkinson's disease cohort. J Parkinsons Dis 2018;8:353–362.
Hiorth YH, Alves G, Larsen JP, et al. Long‐term risk of falls in an incident Parkinson's disease cohort: the Norwegian ParkWest study. J Neurol 2017;264:364–372.
Macleod AD, Dalen I, Tysnes OB, et al. Development and validation of prognostic survival models in newly diagnosed Parkinson's disease. Mov Disord 2018;33:108–116.
Frings L, Henninger F, Treppner M, et al. DAT SPECT predicts survival in patients assessed for differential diagnosis of dementia. J Alzheimers Dis 2021;82:215–220.
Vijiaratnam N, Lawton M, Heslegrave AJ, et al. Combining biomarkers for prognostic modelling of Parkinson's disease. J Neurol Neurosurg Psychiatry 2022;93:707–715.
Sörensen A, Blazhenets G, Rücker G, et al. Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel‐wise cox regression based on FDG PET data. Neuroimage Clin 2019;21:101637.
Weiller C, Reisert M, Glauche V, et al. The dual‐loop model for combining external and internal worlds in our brain. Neuroimage 2022;263:119583.
Coyle‐Gilchrist ITS, Dick KM, Patterson K, et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 2016;86:1736–1743.
Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 2011;68:165.
Costentin G, Derrey S, Gérardin E, et al. White matter tracts lesions and decline of verbal fluency after deep brain stimulation in Parkinson's disease. Hum Brain Mapp 2019;40:2561–2570.
Graff‐Radford J, Lesnick TG, Boeve BF, et al. Predicting survival in dementia with Lewy bodies with hippocampal volumetry. Mov Disord 2016;31:989–994.
Meyer PT, Frings L, Hellwig S. Update on SPECT and PET in parkinsonism—part 2: biomarker imaging of cognitive impairment in Lewy‐body diseases. Curr Opin Neurol 2014;27:398–404.
Hellwig S, Frings L, Amtage F, et al. 18F‐FDG PET is an early predictor of overall survival in suspected atypical parkinsonism. J Nucl Med 2015;56:1541–1546.
Frings L, Blazhenets G, Binder R, et al. More extensive hypometabolism and higher mortality risk in patients with right‐ than left‐predominant neurodegeneration of the anterior temporal lobe. Alzheimers Res Ther 2023;15:11.
Ge J, Wu J, Peng S, et al. Reproducible network and regional topographies of abnormal glucose metabolism associated with progressive supranuclear palsy: multivariate and univariate analyses in American and Chinese patient cohorts. Hum Brain Mapp 2018;39:2842–2858.
Litvan I, MacIntyre A, Goetz CG, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 1998;55:969–978.
Rizzo G, Copetti M, Arcuti S, et al. Accuracy of clinical diagnosis of Parkinson disease. Neurology 2016;86:566–576.